Center for Chemical Genomics

We provide high-throughput screening of extensive small molecule, natural product and siRNA libraries for basic biology and drug discovery projects.

About Us

The Center for Chemical Genomics provides high-throughput screening of extensive small molecule, natural product and siRNA libraries — along with assay development and optimization — for basic biology and drug discovery projects.

Our dedicated staff has years of experience in academic drug discovery and within the pharmaceutical industry, allowing us to provide expert guidance to researchers through every stage of a project.

Our services are available to U-M researchers and to outside academic and industry partners.

If you're a new user, please visit our getting started guide.

Announcements

November 21, 2025

KOMZIFTI™ (ziftomenib), a leukemia treatment based on U-M research, has received FDA approval, making it the first and only once-daily oral therapy for patients with relapsed or refractory NPM1-mutant acute myeloid leukemia. High-throughput screening in the CCG identified some initial hits with the potiential to inhibit menin's interaction with KMT2A in acute myeloid leukemia. Through extensive medicinal chemistry over the next decade, an optimized drug was developed from one of those initial hits.

Our Services

High-Throughput Screening

We offer high-throughput screening of extensive small molecule, natural product and siRNA libraries — along with assay development and optimization — for basic biology and drug discovery projects.

well plate (Credit: entropia_n/iStock/Thinkstock)

Sample Libraries

We have more than 250,000 diverse small molecule compounds, a unique library of more than 50,000 natural product extracts, an extensive siRNA library and a growing library of 7,000-plus FDA-approved drugs and clinical compounds for drug repurposing projects.